Citations

Showing 10 of 108083 citations.

Mayo‐PACC: A parsimonious preclinical Alzheimer's disease cognitive composite comprised of public‐domain measures to facilitate clinical translation
Twohy, Erin , Albertson, Sabrina M., Karstens, Aimee J. , Kremers, Walter K. , Fields, Julie A. , Petersen, Ronald C. , Stricker, Nikki H. , Kremers, Walter K , Karstens, Aimee James , Machulda, Mary M. , Jack, Clifford R. , Knopman, David S. , Mielke, Michelle M.

Mayo Clinic

Alzheimer's & Dementia | December 24, 2022 | Volume: 19 | Issue: 6 | Pages: 2575-2584

10.1002/alz.12895 | PMID 36565459 Get It

Abstract Introduction We aimed to define a Mayo Preclinical Alzheimer's disease Cognitive Composite (Mayo‐PACC) that prioritizes parsimony and use of public domain measures to facilitate clinical translation. Methods Cognitively unimpaired participants aged 65 to 85 at baseline with amyloid PET imaging were included, yielding 428 amyloid negative (A‐) and 186 amyloid positive (A+) individuals with 7 years mean follow‐up. Sensitivity to amyloid‐related cognitive decline was examined using slope estimates derived from linear mixed models (difference in annualized change across A+ and A‐ groups). We compared differences in rates of change between Mayo‐PACC and other composites (A+ > A‐ indicating more significant decline in A+). Results All composites showed sensitivity to amyloid‐related longitudinal cognitive decline (A+ > A‐ annualized change p < 0.05). Comparisons revealed that Mayo‐PACC (AVLT sum of trials 1‐5+6+delay, Trails B, animal fluency) showed comparable longitudinal sensitivity to other composites. Discussion Mayo‐PACC performs similarly to other composites and can be directly translated to the clinic.
Association of Incidentally Discovered Covert Cerebrovascular Disease Identified Using Natural Language Processing and Future Dementia
Kent, David M. , Leung, Lester Y. , Luetmer, Patrick H. , Kallmes, David F. , Nelson, Jason , Fu, Sunyang , Puttock, Eric J. , Zheng, Chengyi , Chen, Wansu , Luetmer, Patrick H , Nelson, Jason , Fu, Sunyang , Puttock, Eric J , Zheng, Chengyi , Kent, David M , Zhou, Yichen , Liu, Hongfang

Mayo Clinic

Journal of the American Heart Association | December 24, 2022 | Volume: 12 | Issue: 1 | Pages: No page available

10.1161/jaha.122.027672 | PMID 36565208 Get It

Background Covert cerebrovascular disease (CCD) has been shown to be associated with dementia in population‐based studies with magnetic resonance imaging (MRI) screening, but dementia risk associated with incidentally discovered CCD is not known. Methods and Results Individuals aged ≥50 years enrolled in the Kaiser Permanente Southern California health system receiving head computed tomography (CT) or MRI for nonstroke indications from 2009 to 2019, without prior ischemic stroke/transient ischemic attack, dementia/Alzheimer disease, or visit reason/scan indication suggestive of cognitive decline or stroke were included. Natural language processing identified incidentally discovered covert brain infarction (id‐CBI) and white matter disease (id‐WMD) on the neuroimage report; white matter disease was characterized as mild, moderate, severe, or undetermined. We estimated risk of dementia associated with id‐CBI and id‐WMD. Among 241 050 qualified individuals, natural language processing identified 69 931 (29.0%) with id‐WMD and 11 328 (4.7%) with id‐CBI. Dementia incidence rates (per 1000 person‐years) were 23.5 (95% CI, 22.9–24.0) for patients with id‐WMD, 29.4 (95% CI, 27.9–31.0) with id‐CBI, and 6.0 (95% CI, 5.8–6.2) without id‐CCD. The association of id‐WMD with future dementia was stronger in younger (aged <70 years) versus older (aged ≥70 years) patients and for CT‐ versus MRI‐discovered lesions. For patients with versus without id‐WMD on CT, the adjusted HR was 2.87 (95% CI, 2.58–3.19) for younger and 1.87 (95% CI, 1.79–1.95) for older patients. For patients with versus without id‐WMD on MRI, the adjusted HR for dementia risk was 2.28 (95% CI, 1.99–2.62) for younger and 1.48 (95% CI, 1.32–1.66) for older patients. The adjusted HR for id‐CBI was 2.02 (95% CI, 1.70–2.41) for younger and 1.22 (95% CI, 1.15–1.30) for older patients for either modality. Dementia risk was strongly correlated with id‐WMD severity; adjusted HRs compared with patients who were negative for id‐WMD by MRI ranged from 1.41 (95% CI, 1.25–1.60) for those with mild disease on MRI to 4.11 (95% CI, 3.58–4.72) for those with severe disease on CT. Conclusions Incidentally discovered CCD is common and associated with a high risk of dementia, representing an opportunity for prevention. The association is strengthened when discovered at younger age, by increasing id‐WMD severity, and when id‐WMD is detected by CT scan rather than MRI.
Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
Patlolla, Sri Harsha , Schaff, Hartzell V. , Nishimura, Rick A. , Eleid, Mackram F. , Geske, Jeffrey B. , Ommen, Steve R. , Harsha Patlolla, Sri , Schaff, Hartzell , Geske, Jeffrey B , Nishimura, Rick A

Mayo Clinic

Journal of the American Heart Association | December 24, 2022 | Volume: 12 | Issue: 1 | Pages: No page available

10.1161/jaha.122.026661 | PMID 36565202 Get It

Background Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. Methods and Results Using the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in‐hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57–0.73]; P <0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66–0.92]; P =0.003) were less likely to receive SRT. Among admissions undergoing SRT, in‐hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81–6.30], P <0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00–4.11]; P =0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. Conclusions Among obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in‐hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences.
Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome
Maalouf, Elisia, Grover, Madhusudan

Mayo Clinic

Alimentary Pharmacology & Therapeutics | December 24, 2022 | Volume: 57 | Issue: 2 | Pages: 261-262

10.1111/apt.17304 | PMID 36565004 Get It

LINKED CONTENTThis article is linked to Lembo et al paper. To view this article, visit https://doi.org/10.1111/apt.17274
Nivolumab, Brentuximab Vedotin, +/- Bendamustine For R/R Hodgkin Lymphoma in Children, Adolescents, and Young Adults
Harker‐Murray, Paul , Mauz‐Körholz, Christine , Leblanc, Thierry , Mascarin, Maurizio , Michel, Gérard , Cooper, Stacy , Beishuizen, Auke , Leger, Kasey J. , Amoroso, Loredana , Buffardi, Salvatore, Rigaud, Charlotte , Lisano, Julie , Sacchi, Mariana, Cole, Peter D. , Drachtman, Richard A. , Kelly, Kara M. , Daw, Stephen , Hoppe, Bradford S , Mauz-Koerholz, Christine , Leblanc, Thierry , Hoppe, Bradford S. , Francis, Stephen

Mayo Clinic

Blood | December 24, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2022017118 | PMID 36564047 Get It

Children, adolescents, and young adults (CAYA) with relapsed/refractory classical Hodgkin lymphoma (cHL) without complete metabolic response (CMR) before autologous hematopoietic cell transplantation (auto-HCT) have poor survival outcomes. CheckMate 744, a phase 2 study for CAYA (aged 5-30 years) with relapsed/refractory cHL, evaluated a risk-stratified, response-adapted approach with nivolumab plus brentuximab vedotin (BV) followed by BV plus bendamustine for patients with suboptimal response. Risk stratification was primarily based on time to relapse, prior treatment, and presence of B symptoms. We present the primary analysis of the standard-risk cohort. Data from the low-risk cohort are reported separately. Patients received 4 induction cycles with nivolumab plus BV; those without CMR (Deauville score &gt;3, Lugano 2014) received BV plus bendamustine intensification. Patients with CMR after induction or intensification proceeded to consolidation (high-dose chemotherapy/auto-HCT per protocol). Primary endpoint was CMR any time before consolidation. Forty-four patients were treated. Median age was 16 years. At a minimum follow-up of 15.6 months, 43 patients received 4 induction cycles (1 discontinued); 11 of whom received intensification, 32 proceeded to consolidation. CMR rate was 59% after induction with nivolumab plus BV, and 94% any time before consolidation (nivolumab plus BV ± BV plus bendamustine). One-year PFS rate was 91%. During induction, 18% of patients experienced grade 3/4 treatment-related adverse events. This risk-stratified, response-adapted salvage strategy had high CMR rates with limited toxicities in CAYA with relapsed/refractory cHL. Most patients did not require additional chemotherapy (bendamustine intensification). Additional follow-up is needed to confirm durability of disease control. ClinicalTrials.gov: NCT02927769.
Comment: Introducing Neurology Education in 2035
Gross, Robert A. , Jones, Lyell K , Jones, Lyell K.

Mayo Clinic

Neurology | December 23, 2022 | Volume: 100 | Issue: 12 | Pages: 578-578

10.1212/wnl.0000000000206792 | PMID 36564203 Get It

Artifacts and Technical Considerations at Contrast-enhanced US
Fetzer, David T. , Vijay, Kanupriya , Caserta, Melanie P. , Patterson‐Lachowicz, Amber , Dahiya, Nirvikar , Rodgers, Shuchi K. , Rodgers, Shuchi K

Mayo Clinic

RadioGraphics | December 23, 2022 | Volume: 43 | Issue: 2 | Pages: No page available

10.1148/rg.220093 | PMID 36563094 Get It

Teaching NeuroImage: Intracranial Solitary Fibrous Tumor With Liver Metastasis
Webb, Mason , Campian, Jian , Sener, Uğur , Webb, Mason James , Campian, Jian L , Sener, Ugur

Mayo Clinic

Neurology | December 23, 2022 | Volume: 100 | Issue: 18 | Pages: 884-885

10.1212/wnl.0000000000206822 | PMID 36564211 Get It

The Effect of Glucagon-Like Peptide 1 Receptor Blockade on Glucagon-Induced Stimulation of Insulin Secretion
Farahani, Rahele A., Welch, Andrew A. , LAURENTI, MARCELLO C. , Man, Chiara Dalla , Vella, Adrian , Egan, Aoife M. , Vella, Adrian , Dalla Man, Chiara , Cobelli, Claudio

Mayo Clinic

Diabetes | December 23, 2022 | Volume: 72 | Issue: 4 | Pages: 449-454

10.2337/db22-0709 | PMID 36562995 Get It

Data from transgenic rodent models suggest that glucagon acts as an insulin secretagogue by signaling through the glucagon-like peptide 1 receptor (GLP-1R) present on β-cells. However, its net contribution to physiologic insulin secretion in humans is unknown. To address this question, we studied individuals without diabetes in two separate experiments. Each subject was studied on two occasions in random order. In the first experiment, during a hyperglycemic clamp, glucagon was infused at 0.4 ng/kg/min, increasing by 0.2 ng/kg/min every hour for 5 h. On one day, exendin-9,39 (300 pmol/kg/min) was infused to block GLP-1R, while on the other, saline was infused. The insulin secretion rate (ISR) was calculated by nonparametric deconvolution from plasma concentrations of C-peptide. Endogenous glucose production and glucose disappearance were measured using the tracer-dilution technique. Glucagon concentrations, by design, did not differ between study days. Integrated ISR was lower during exendin-9,39 infusion (213 ± 26 vs. 191 ± 22 nmol/5 h, saline vs. exendin-9,39, respectively; P = 0.02). In the separate experiment, exendin-9,39 infusion, compared with saline infusion, also decreased the β-cell secretory response to a 1-mg glucagon bolus. These data show that, in humans without diabetes, glucagon partially stimulates the β-cell through GLP-1R.
Impact of Neck PET/CT Positivity on Survival Outcomes—Visual and Quantitative Assessment
Stack, Brendan C. , Duan, Fenghai , Romanoff, Justin , Sicks, JoRean D., Subramaniam, Rathan M. , Lowe, Val J.

Mayo Clinic

Clinical Nuclear Medicine | December 23, 2022 | Volume: 48 | Issue: 2 | Pages: 126-131

10.1097/rlu.0000000000004483 | PMID 36562743 Get It

Introduction FDG PET/CT was prospectively studied in 287 cN0 head and neck cancer patients in ACRIN 6685, and additional analysis of neck FDG uptake upon recurrence-free survival (RFS) and overall survival (OS) was performed. Patients and Methods Two hundred eight had analyzable data. Survival analysis was performed to compare RFS and OS based on neck FDG visual assessment (VA) and SUVmax. For SUVmax, the optimal thresholds were calculated using conditional inference trees on a randomly selected 70% training data set and validated using the remaining 30% of data. Kaplan-Meier curves with log-rank tests were generated for the patient groups based on VA and optimal SUVmax thresholds, and the hazards ratios (HRs) and 95% confidence intervals (CIs) were also calculated. Hypothesis testing was set at a significance level of 0.05. Results A total of 73.9% of bilateral cN0 and 50.0% of unilateral cN0 were alive at the end of the study with the remaining being dead or lost to follow-up. Overall survival median follow-up time was 24.0 months (interquartile range, 15.8–25.3; range, 0–37.0). A total of 63.3% of bilateral cN0 and 42.5% of unilateral cN0 patients remained disease free during the study. Recurrence-free survival median follow-up time was 23.9 months (interquartile range, 12.4–25.2; range, 0–35.6). Visual assessment of necks by our panel of radiologists was significantly associated with RFS (HR [95% CI], 2.30 [1.10–4.79]; P = 0.02), but not with OS (HR [95% CI], 1.64 [0.86–3.14]; P = 0.13). The optimal SUVmax thresholds were 2.5 for RFS and 5.0 for OS. For SUVmax assessment, applying the optimal thresholds to the 30% test data yielded HRs (95% CIs) of 2.09 (0.61–7.14; P = 0.23) for RFS and 3.42 (1.03–11.41; P = 0.03) for OS. The SUVmax threshold of 5.0 was significantly associated with RFS (HR [95% CI], 5.92 [1.79–19.57]; P < 0.001). Conclusions Neck FDG uptake by VA is significant for RFS. An SUVmax threshold of 5.0 is significantly associated with OS and RFS.